No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
1 out of 7 registries used, show all original rules. |
589 |
4. Check minimum number of eventsNone |
589 |
5. Include endpointsNone |
589 |
6. Filter based on genotype QC (FinnGen only) |
521 |
Control definitions (FinnGen only)
- Control exclude
- L12_URTICARIAERYTHEMA
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Universal erythroderma, KELA reimbursement
based on the number of shared cases.
Similar with more cases:
- Atopic dermatitis, strict definition with reimbursement
- Urticaria and erythema
- Diseases of the skin and subcutaneous tissue
- Any reimbursement code in KELA
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 3118 | 1019 | 2077 |
| Only index persons | 2650 | 908 | 1742 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.05 | 0.03 | 0.06 |
| Only index persons | 0.06 | 0.03 | 0.07 |
| Median age at first event (years) | |||
| Whole population | 50.11 | 51.31 | 49.42 |
| Only index persons | 48.21 | 49.83 | 47.37 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 521 | 193 | 328 |
| Unadjusted period prevalence (%) | 0.12 | 0.07 | 0.15 |
| Median age at first event (years) | 47.56 | 47.22 | 47.76 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 537
- Matched controls
- 5370
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
E000001, ,
ATC
25.6
319.6
408
590
D07XC01
ATC
betamethasone; topical
23.2
318.8
344
383
L04AX03
ATC
methotrexate; systemic
26.7
307.7
310
261
L40.0
ICD-10 Finland
Psoriasis vulgaris
95.8
307.7
333
90
D05BB02
ATC
acitretin; oral
185.9
307.7
344
51
D05AX52
ATC
calcipotriol, combinations; topical
44.9
307.7
282
129
D05AX02
ATC
calcipotriol; topical
79.1
307.7
280
73
134
Kela drug reimbursment
General erythroderma
+∞
307.7
537
*
E000003, ,
ATC
32.1
271.3
194
93
D05AX03
ATC
calcitriol; topical
84.9
259.0
139
22
E000002, ,
ATC
17.6
245.8
265
282
WXQ27
NOMESCO Finland
UVB narrow spectrum light therapy
91.6
228.8
121
17
L40.5
ICD-10 Finland
Arthropathic psoriasis
57.4
226.8
131
30
L04AD01
ATC
ciclosporin; systemic
53.3
216.5
127
31
M07.3*L40.5
ICD-10 Finland
Other psoriatic arthropathies
44.8
211.6
130
38
D07AB08
ATC
desonide; topical
14.5
210.7
254
313
D07AD01
ATC
clobetasol; topical
13.3
210.5
306
486
D07AC01
ATC
betamethasone; topical
26.5
210.4
482
1336
E0000UV, ,
ATC
41.8
207.4
506
1508
TQW80
NOMESCO Finland
Local dermatologic skincare
32.6
186.1
126
50
L40.8
ICD-10 Finland
Other psoriasis
88.6
179.3
95
13
317
Kela drug reimbursment
Topical pimecrolimus and tacrolimus
41.2
174.8
109
33
L40.9
ICD-10 Finland
Psoriasis, unspecified
52.5
169.6
99
23
319
Kela drug reimbursment
Adalimumab, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, sekukinumab and ustekinumab (skin psoriasis)
263.6
168.8
165
9
L04AA01
ATC
[U] ciclosporin
66.5
160.3
89
16
D07AC13
ATC
mometasone; topical
9.8
153.4
370
989
D07AB02
ATC
hydrocortisone butyrate; topical
9.7
150.8
372
1014
D11AH01
ATC
tacrolimus; topical
68.9
148.9
82
14
E000006, ,
ATC
14.1
144.2
151
145
D02AE01
ATC
carbamide; topical
13.2
142.4
157
163
D02AX
ATC
Other emollients and protectives
22.5
140.3
109
60
L40
ICD-10 Finland
Psoriasis
28.6
133.4
93
39
E000007, ,
ATC
14.1
125.4
128
117
L20.0
ICD-10 Finland
Besnier prurigo
11.5
123.6
149
174
L01BA01
ATC
methotrexate; systemic
18.4
122.9
105
70
L04AB04
ATC
adalimumab; parenteral
27.9
118.5
83
35
D07AA02
ATC
hydrocortisone; topical
8.0
117.2
217
422
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
9.2
113.2
167
251
L26
ICD-10 Finland
Exfoliative dermatitis
+∞
102.4
95
*
N05BB01
ATC
hydroxyzine; systemic
11.2
100.9
119
133
D07BA04
ATC
hydrocortisone and antiseptics; topical
8.4
100.4
159
257
D09AB01
ATC
zinc bandage without supplements; topical
29.1
90.8
62
24
D11AX14
ATC
[U] tacrolimus
56.2
89.4
51
10
M07.3
ICD-10 Finland
Other psoriatic arthropathies
38.2
87.9
55
16
D05AA
ATC
Tars
35.1
79.6
51
16
D07BB04
ATC
hydrocortisone butyrate and antiseptics; topical
6.2
78.5
173
385
6961A
ICD-9 Finland
Psoriasis and similar disorders, Other psoriasis[PSORIASIS VULGARIS]
800.7
72.9
70
*
69619
ICD-8 Finland
Psoriasis and similar disorders, Psoriasis alia sive NUD (vulgaris)
108.7
69.9
75
8
D01AC20
ATC
imidazoles/triazoles in combination with corticosteroids; topical
4.7
66.6
237
776
L04AC05
ATC
ustekinumab; parenteral
111.0
63.5
68
7
S91
ICPC
Psoriasis
26.5
62.7
44
18
L04AB01
ATC
etanercept; parenteral
24.5
62.2
45
20
XQ848
NOMESCO Finland
Dermatological photography
12.4
60.8
63
57
R2130
NOMESCO Finland
Counselling and guidance which enhance independent living
5.8
53.0
112
234
L04AC10
ATC
secukinumab; parenteral
79.3
51.2
57
8
E000004, ,
ATC
14.7
49.9
46
34
395
Kela drug reimbursment
Dupilumab
499.1
47.1
46
*
L04AC13
ATC
ixekizumab; parenteral
134.5
46.6
49
*
D11AH02
ATC
pimecrolimus; topical
87.8
43.7
48
6
D11AH05
ATC
dupilumab; topical
451.6
42.8
42
*
H02AB06
ATC
prednisolone; systemic
3.4
41.8
345
1841
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
4.6
41.1
116
306
XQ800
NOMESCO Finland
Prick test
6.1
39.8
75
139
Z01.5
ICD-10 Finland
Diagnostic skin and sensitization tests
5.1
38.3
91
208
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
6.0
37.9
73
138
L04AC18
ATC
risankizumab; parenteral
204.0
37.3
38
*
D07AC14
ATC
methylprednisolone aceponate; topical
6.4
36.7
65
113
L30.3
ICD-10 Finland
Infective dermatitis
7.6
35.8
53
76
L20
ICD-10 Finland
Atopic dermatitis
8.9
35.6
46
56
L04AC16
ATC
guselkumab; systemic
358.8
34.3
34
*
R06AE07
ATC
cetirizine; oral
2.9
33.3
282
1465
L40.4
ICD-10 Finland
Guttate psoriasis
175.4
32.1
33
*
R06AE09
ATC
levocetirizine; oral
3.8
31.5
115
362
XQ802
NOMESCO Finland
Epicutan test
7.3
31.5
48
71
D07BC01
ATC
betamethasone and antiseptics; topical
3.8
30.2
109
340
313
Kela drug reimbursment
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab, tocilizumab and ustekinumab (rheumatoid diseases)
9.4
30.1
37
42
D07CC01
ATC
betamethasone and antibiotics; topical
3.5
29.1
117
391
281
Kela drug reimbursment
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab and tocilizumab
9.5
28.9
35
39
M07.0*L40.5
ICD-10 Finland
Distal interphalangeal psoriatic arthropathy
147.4
26.9
28
*
69100
ICD-8 Finland
Infantile eczema and related conditions, Eczema atopicum. Prurigo Besnier. Eczema pruriginosum allergicum
10.2
25.2
29
30
R06AX27
ATC
desloratadine; oral
2.7
24.1
185
883
377
Kela drug reimbursment
Apremilast and dimethyl fumarate (psoriasis)
91.0
23.9
26
*
D11AX15
ATC
[U] pimecrolimus
130.9
23.8
25
*
L04AA32
ATC
apremilast; oral
130.9
23.8
25
*
6960A
ICD-9 Finland
Psoriasis and similar disorders, Psoriatic arthropathy
68.1
23.0
26
*
L40.1
ICD-10 Finland
Generalized pustular psoriasis
+∞
22.0
21
*
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.4
21.6
306
1911
D07XB05
ATC
dexamethasone; topical
6.5
20.9
35
57
D05AC01
ATC
dithranol; topical
80.1
20.8
23
*
TQW99
NOMESCO Finland
Other minor procedure on skin
4.5
20.8
54
131
L04AX01
ATC
azathioprine; systemic
5.0
20.7
46
98
ZX112
NOMESCO Finland
Subcutaneous
7.2
19.7
30
44
A46
ICD-10 Finland
Erysipelas
2.8
19.6
115
472
L04AA11
ATC
[U] etanercept
57.2
19.1
22
*
L04AC21
ATC
bimekizumab; systemic
+∞
17.8
17
*
SPAT1262
SPAT
Handing over of treatment supplies
2.6
17.4
119
526
WXQ12
NOMESCO Finland
Psoralen - Ultraviolet A therapy with local sensitivisation
43.6
17.4
21
5
J01DA09
ATC
[U] cefadroxil
2.3
17.3
171
895
C84.0
ICD-10 Finland
Mycosis fungoides
51.8
17.1
20
*
H02AB09
ATC
hydrocortisone; systemic
6.3
17.0
29
48
S01GX01
ATC
cromoglicic acid; ophthalmic
2.6
16.9
121
547
L20.9
ICD-10 Finland
Atopic dermatitis, unspecified
4.9
16.8
38
82
TNX10
NOMESCO Finland
Arthrocentesis, unspecified region, unspecified region
3.7
16.7
55
159
J01FF01
ATC
clindamycin; systemic
2.3
16.5
176
949
H02AB07
ATC
prednisone; oral
2.7
15.9
94
385
D05AX05
ATC
tazarotene; topical
61.9
15.8
18
*
WXQ10
NOMESCO Finland
Psoralen - Ultraviolet A therapy with systemic sensitivisation
+∞
15.7
15
*
QXA25
NOMESCO Finland
Destruction of lesion of skin, site unspecified
5.2
15.7
33
67
D05AX
ATC
Other antipsoriatics for topical use
87.7
15.6
17
*
D07XB01
ATC
flumetasone; topical
20.8
15.2
22
11
A07EC01
ATC
sulfasalazine; oral, rectal
3.3
15.2
62
206
69600
ICD-8 Finland
Psoriasis and similar disorders, Psoriatic arthropathy
58.4
14.9
17
*
RS340, ,
NOMESCO Finland
+∞
14.6
14
*
WQ031, ,
NOMESCO Finland
+∞
14.6
14
*
ZY010
NOMESCO Finland
Hospital outpatient
3.9
14.6
45
124
C01CA24
ATC
epinephrine; parenteral
3.7
14.4
47
135
L30.9
ICD-10 Finland
Dermatitis, unspecified
2.3
14.2
128
637
D07AB01
ATC
clobetasone; topical
4.8
14.2
33
73
J01DA01
ATC
[U] cefalexin
2.1
14.2
346
2509
ND2AA
NOMESCO Finland
Hand and fingers X-ray examination
2.9
13.9
72
274
M07.0
ICD-10 Finland
Distal interphalangeal psoriatic arthropathy
143.5
13.5
14
*
NH3EA
NOMESCO Finland
Feet X-ray examination with load
10.1
13.4
26
27
J30.10
ICD-10 Finland
Allergic rhinitis due to pollen
3.7
13.1
42
119
A41.0
ICD-10 Finland
Sepsis due to Staphylococcus aureus
5.2
12.5
26
52
D11AH04
ATC
alitretinoin; oral
133.0
12.5
13
*
SPAT1148
SPAT
Treatment of chronic ulcer or burn
2.5
12.2
86
382
EB1HA
NOMESCO Finland
Panorama tomography of teeth and jaws or similar X-ray examination
1.9
11.8
233
1539
B07.9
ICD-10 Finland
Verruca simplex
4.3
11.7
31
76
SPAT1222
SPAT
Counselling/guidance promoting independent living
2.4
11.6
90
417
H04.10
ICD-10 Finland
Dry eye syndrome
2.6
11.6
72
301
L04AA13
ATC
[U] leflunomide
5.9
11.6
21
37
XX9XT
NOMESCO Finland
Other radiological intervention
+∞
11.5
11
*
SPAT1263
SPAT
Sampling
1.9
11.5
224
1470
R06AX26
ATC
fexofenadine; oral
3.2
11.3
45
147
6918B
ICD-9 Finland
Atopic dermatitis and related conditions, Other atopic dermatitis and related conditions[ECZEMA ATOPICUM]
13.1
11.2
19
15
J01DB01
ATC
cefalexin; oral
2.2
10.9
446
3700
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
2.7
10.6
62
251
J30.3
ICD-10 Finland
Other allergic rhinitis
4.3
10.5
27
65
WQ066, ,
NOMESCO Finland
+∞
10.4
10
*
RJ420, ,
NOMESCO Finland
17.1
9.9
15
9
SPAT1254
SPAT
Administration of medicine
2.2
9.9
87
425
L27.2
ICD-10 Finland
Dermatitis due to ingested food
26.6
9.9
13
5
D06AX01
ATC
fusidic acid; topical
2.5
9.7
63
268
S01XA20
ATC
artificial tears and other indifferent preparations; ophthalmic
1.8
9.7
215
1449
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
2.3
9.7
83
401
L40.3
ICD-10 Finland
Pustulosis palmaris et plantaris
10.3
9.6
18
18
R06AX13
ATC
loratadine; oral
2.2
9.5
85
418
N06AA12
ATC
doxepin; systemic
3.1
9.5
41
141
9700/3-C44.9
ICD-O-3
Mycosis fungoides of skin, NOS
101.8
9.4
10
*
299, ,
Kela drug reimbursment
101.8
9.4
10
*
L08.0
ICD-10 Finland
Pyoderma
12.6
9.4
16
13
PJ2AE
NOMESCO Finland
Lymphnode ultrasound examination
22.2
9.4
13
6
J45.0
ICD-10 Finland
Predominantly allergic asthma
2.6
9.3
56
230
SPAT1250
SPAT
Comprehensive monitoring of chronic illness
1.9
8.9
142
860
RJ411, ,
NOMESCO Finland
12.8
8.9
15
12
SPAT1256
SPAT
Intramuscular and subcutaneous injection
1.8
8.9
216
1486
J02AB02
ATC
ketoconazole; oral
4.1
8.9
24
60
SPAT1249
SPAT
Treatment-related counselling outside office
1.8
8.8
199
1339
E27.3
ICD-10 Finland
Drug-induced adrenocortical insufficiency
20.4
8.5
12
6
ZY020
NOMESCO Finland
Telephone, letter or other consultation without direct patient contact
2.7
8.5
48
191
L44.0
ICD-10 Finland
Pityriasis rubra pilaris
91.4
8.4
9
*
Q80.8
ICD-10 Finland
Other congenital ichthyosis
+∞
8.4
8
*
A41.9
ICD-10 Finland
Sepsis, unspecified
3.5
8.3
28
82
SPAT1156
SPAT
Guidance concerning treatment of rash and skin
2.2
8.3
76
376
QAA25
NOMESCO Finland
Destruction of lesion of head or neck
4.3
8.3
21
50
T90
ICPC
Diabetes non-insulin dependent
1.8
8.1
141
875
6929X
ICD-9 Finland
Contact dermatitis and other eczema, Unspecified cause[DERMATITITIS ARTEFACTA NUD]
33.9
8.1
10
*
RJ421, ,
NOMESCO Finland
22.4
8.0
11
5
H16.9
ICD-10 Finland
Keratitis, unspecified
4.7
7.9
18
39
N17.9
ICD-10 Finland
Acute renal failure, unspecified
3.1
7.9
32
106
NH3AA
NOMESCO Finland
Foot and toes X-ray examination
2.5
7.8
51
218
203
Kela drug reimbursment
Chronic asthma and similar chronic obstructive pulmonary diseases
1.9
7.8
109
631
103
Kela drug reimbursment
Diabetes, insulin-treated
1.8
7.7
158
1028
A10BA02
ATC
metformin; oral
1.7
7.6
165
1089
RS121, ,
NOMESCO Finland
12.1
7.6
13
11
L50.8
ICD-10 Finland
Other urticaria
25.4
7.6
10
*
3029
Kela drug reimbursment
Upadacitinib
25.4
7.6
10
*
SPAT1312
SPAT
General health counselling
1.8
7.6
158
1033
M07.2*L40.5
ICD-10 Finland
Psoriatic spondylitis
81.2
7.4
8
*
D05AD01
ATC
trioxysalen; topical
81.2
7.4
8
*
215
Kela drug reimbursment
Diabetes, non-insulin-treated
1.8
7.4
142
904
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
2.6
7.4
42
168
L27.0
ICD-10 Finland
Generalized skin eruption due to drugs and medicaments
8.5
7.4
15
18
WZB00
NOMESCO Finland
Telephone prescription or other care instructions
1.7
7.3
156
1024
1543, ,
Kela drug reimbursment
+∞
7.3
7
*
R06AX22
ATC
ebastine; oral
2.0
7.3
87
476
D07AC03
ATC
desoximetasone; topical
5.9
7.3
19
33
L50.9
ICD-10 Finland
Urticaria, unspecified
4.6
7.2
17
38
RS211, ,
NOMESCO Finland
30.5
7.2
9
*
J05AB01
ATC
aciclovir; systemic
1.8
7.2
115
694
S01GX08
ATC
ketotifen; ophthalmic
3.1
7.1
29
96
J45.9
ICD-10 Finland
Asthma, unspecified
1.9
7.1
102
593
ND2DA
NOMESCO Finland
Bilateral hand X-ray examination
6.2
7.1
18
30
R03AC02
ATC
salbutamol; inhalant
1.6
7.1
282
2173
D07CA01
ATC
hydrocortisone and antibiotics; topical
2.1
7.1
75
393
S01CA01
ATC
dexamethasone and antiinfectives; ophthalmic
1.7
7.0
171
1164
EBA15
NOMESCO Finland
Extraction of multiple teeth
3.1
6.9
29
98
L28.1
ICD-10 Finland
Prurigo nodularis
14.0
6.9
11
8
L04AF03
ATC
upadacitinib; oral
40.6
6.8
8
*
WXQ24
NOMESCO Finland
UVB/UVA light therapy
40.6
6.8
8
*
N18.9
ICD-10 Finland
Chronic kidney disease, unspecified
2.5
6.7
41
170
SPAT1310
SPAT
Counselling related to known health issue
1.7
6.7
156
1046
6929B
ICD-9 Finland
Contact dermatitis and other eczema, Unspecified cause[ECZEMA INFECTIOSUM]
22.8
6.7
9
*
L01.1
ICD-10 Finland
Impetiginization of other dermatoses
22.8
6.7
9
*
L50.0
ICD-10 Finland
Allergic urticaria
7.0
6.6
15
22
J45
ICD-10 Finland
Asthma
2.2
6.5
54
257
WQ021, ,
NOMESCO Finland
70.7
6.4
7
*
E0001A1, ,
ATC
4.1
6.4
17
42
WW200
NOMESCO Finland
Immunization
3.7
6.4
20
56
WZC30
NOMESCO Finland
Teaching
1.8
6.3
95
560
S97
ICPC
Chronic ulcer skin
2.4
6.3
44
194
E11.9
ICD-10 Finland
Type 2 diabetes mellitus, without complications
1.7
6.3
137
900
QDA25
NOMESCO Finland
Destruction of lesion of skin of lower limb
18.3
6.3
9
5
L97
ICD-10 Finland
Ulcer of lower limb, not elsewhere classified
3.1
6.3
25
82
I10
ICD-10 Finland
Essential (primary) hypertension
1.6
6.3
318
2566
Q80.2
ICD-10 Finland
Lamellar ichthyosis
+∞
6.3
6
*
C84.1
ICD-10 Finland
Sézary disease
+∞
6.3
6
*
WQ053, ,
NOMESCO Finland
+∞
6.3
6
*
75720
ICD-8 Finland
Congenital anomalies of skin, hair and nails, Iethyosis congenita
+∞
6.3
6
*
SPAT1223
SPAT
Implementation of physical therapy rehabilitation plan
1.7
6.2
138
910
E000005, ,
ATC
27.0
6.2
8
*
Z3231
NOMESCO Finland
Registered nurse
1.7
6.2
142
944
SPAT1301
SPAT
No procedures
1.7
6.1
154
1050
L23.8
ICD-10 Finland
Allergic contact dermatitis due to other agents
12.7
6.1
10
8
ZXC50
NOMESCO Finland
Cryotherapy
3.2
6.1
23
73
RS221, ,
NOMESCO Finland
6.1
6.0
15
25
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
437
2591
4.69
47.54
15.8
10.4
4.09
4.18
e9/l
0.48
424
2267
76
143
6.03
39.73
1.9
1.5
0.02
0.10
iu/ml
—
6
30
97
281
3.99
29.83
1.9
1.3
3090.88
270.80
u/ml
3.87
89
256
338
2018
2.82
29.37
22.3
11.8
0.00
0.00
e9/l
0.59
320
1663
237
1314
2.44
22.05
5.3
3.8
0.00
0.01
estimate
0.78
116
441
109
454
2.76
18.00
4.9
3.4
—
—
—
0
0
25
14
18.67
16.61
1.9
1.1
9.04
9.03
ug/l
0.00
25
14
438
3415
2.53
15.94
13.4
8.8
83.12
78.71
u/l
1.28
428
3246
427
3294
2.45
15.87
7.0
4.2
13.39
11.69
mm/h
1.63
405
3085
163
892
2.19
14.45
2.0
1.7
148092009.31
20469797.00
pmol/l
0.58
131
767
216
1320
2.06
14.30
5.2
3.2
0.00
0.07
estimate
0.58
112
384
82
343
2.64
13.22
5.3
4.7
1.22
1.22
mmol/l
0.46
71
303
269
1813
1.97
13.21
5.7
3.7
0.01
0.02
estimate
0.48
116
410
26
28
9.70
13.11
1.6
1.4
22.58
26.24
%
0.14
11
21
329
2385
1.98
12.95
5.6
3.8
0.01
3.28
estimate
0.50
131
495
111
541
2.33
12.86
3.9
4.6
233.37
238.13
u/l
0.25
100
516
325
2362
1.95
12.51
5.5
3.8
0.00
0.00
estimate
-0.00
130
485
27
56
5.02
12.50
1.3
1.3
—
—
—
0
0
327
2406
1.92
11.85
5.6
3.8
0.02
0.66
estimate
0.48
122
454
16
8
20.56
11.19
2.3
1.1
—
—
—
0
0
50
179
2.98
10.75
1.8
2.0
10.29
4.97
iu/ml
—
9
50
139
795
2.01
10.53
3.1
3.5
0.80
0.82
mmol/l
0.85
129
760
40
127
3.32
10.50
2.1
1.7
—
—
—
0
0
169
1045
1.90
10.13
3.3
2.6
6.12
4.28
e6/l
0.45
158
950
24
56
4.44
9.68
2.1
2.9
33.13
33.32
pg
0.08
24
56
290
2170
1.73
8.83
16.4
14.0
1.20
1.24
inr
1.03
261
1802
76
376
2.19
8.33
1.8
3.1
66.67
66.62
g/l
0.02
65
349
185
1238
1.75
8.27
2.9
2.9
360.87
357.21
umol/l
0.17
167
1107
250
1827
1.69
8.05
4.5
3.9
38.57
69.28
ng/l
0.47
183
1309
218
1538
1.70
8.00
5.1
4.1
15.84
8.72
mg/mmol
1.04
141
1015
48
197
2.58
7.99
1.9
2.0
0.91
1.91
ug/l
0.94
39
176
35
125
2.93
7.58
1.6
1.2
—
—
—
0
0
84
449
2.03
7.51
3.1
2.0
270.06
389.12
nmol/l
8.38
78
422
18
28
6.61
7.47
2.0
2.2
—
—
—
0
0
170
1145
1.71
7.26
2.6
2.1
3.34
2.91
mg/l
1.28
139
1003
264
2015
1.61
6.79
5.9
5.1
34.40
35.76
g/l
3.14
247
1905
81
448
1.95
6.55
2.5
2.3
0.20
0.21
g/l
0.49
72
418
21
60
3.60
6.50
1.2
1.1
—
—
—
0
0
25
81
3.19
6.39
1.1
1.1
3.70
0.93
u/ml
0.55
20
48
116
727
1.76
6.31
2.8
2.4
2.42
2.29
g/l
1.23
100
677
218
1626
1.57
5.95
3.8
3.4
7.53
8.23
mmol/l
1.62
179
1380
22
70
3.23
5.80
1.1
1.1
11.42
1.98
u/ml
1.63
17
40
302
2434
1.55
5.78
6.7
7.3
11.36
11.88
umol/l
0.37
288
2334
107
681
1.71
5.46
2.9
2.4
21.41
23.13
%
0.61
93
639
13
22
6.03
5.25
1.2
1.0
1420.77
1552.41
miu/ml
0.14
13
22
118
780
1.66
5.21
3.0
2.4
12.43
13.27
umol/l
0.60
106
730
204
1535
1.53
5.19
3.8
3.3
56.34
96.05
e6/l
0.39
176
1165
112
732
1.67
5.16
2.1
1.7
1257.63
1171.28
nmol/l
0.50
85
570
15
40
3.83
5.12
1.5
1.6
—
—
—
0
0
248
1953
1.50
5.04
2.7
2.4
73.61
75.74
nmol/l
0.57
224
1767
211
1608
1.51
5.02
4.3
3.5
37.78
34.93
u/l
0.57
196
1519
99
639
1.67
4.77
6.7
5.6
1.06
1.02
mmol/l
0.75
93
596
143
1018
1.55
4.59
1.4
1.3
3.63
1.33
u/ml
0.60
49
284
73
438
1.77
4.56
9.7
6.4
12.87
9.59
mmol/l
2.37
68
420
194
1482
1.48
4.44
2.9
2.7
51.19
62.98
u/l
1.94
181
1393
15
45
3.40
4.35
1.3
1.2
—
—
—
0
0
19
67
2.90
4.27
1.5
1.6
—
—
—
0
0
34
163
2.16
4.07
1.8
4.3
29.72
45.93
mg/l
0.70
21
139
34
163
2.16
4.07
1.8
4.3
57.17
93.34
mg/l
0.38
20
137
28
125
2.31
3.97
1.3
1.7
—
—
—
0
0
32
152
2.18
3.93
1.9
3.8
2.38
2.75
ratio
0.10
15
89
416
3727
1.52
3.92
31.7
20.0
13.98
13.63
%
5.51
410
3692
22
92
2.45
3.60
1.5
1.9
—
—
—
0
0
319
2754
1.39
3.41
6.7
5.2
7.10
6.71
mmol/l
1.88
307
2621
49
286
1.78
3.38
4.6
3.2
1.32
1.91
mmol/l
0.43
38
218
14
51
2.79
3.00
1.3
1.6
8.37
4.68
umol/l
—
7
38
470
4391
1.56
2.97
25.5
16.3
20.31
24.81
mg/l
2.88
427
3622
44
261
1.75
2.90
4.2
4.0
48.45
47.92
%
0.04
44
256
180
1448
1.37
2.85
2.2
2.2
142.89
320.20
u/l
1.89
170
1383
102
743
1.46
2.85
1.4
1.3
12.79
10.72
u/ml
0.10
50
287
166
1319
1.37
2.83
3.7
3.2
0.33
0.50
e6/l
0.87
142
962
8
18
4.49
2.80
3.9
5.3
—
—
—
0
0
38
220
1.78
2.73
1.7
1.7
1.54
1.50
g/l
0.08
29
199
8
21
3.85
2.47
4.1
2.0
—
—
—
0
0
22
110
2.04
2.44
1.4
1.5
0.70
0.93
nmol/l
1.03
17
99
174
1423
1.33
2.41
3.6
3.3
2570.04
1249.47
ng/l
0.72
145
1212
68
476
1.49
2.32
4.2
3.3
1.77
1.98
mmol/l
0.18
53
407
9
28
3.25
2.31
1.2
1.5
—
—
—
0
0
10
34
2.98
2.29
1.8
3.5
1128.10
1038.82
mg
—
10
34
94
1228
0.72
2.28
2.8
3.1
0.57
0.76
ug/l
3.03
56
768
15
66
2.31
2.26
1.5
1.6
—
—
—
0
0
9
29
3.14
2.23
1.2
1.6
—
—
—
0
0
16
73
2.23
2.23
1.4
1.3
—
—
—
0
0
261
2274
1.29
2.22
8.8
7.5
1.20
1.21
mmol/l
1.77
201
1988
5
9
5.60
2.22
1.2
1.0
—
—
—
0
0
25
136
1.88
2.21
1.4
1.7
—
—
—
0
0
26
146
1.82
2.10
1.4
1.7
—
—
—
0
0
11
43
2.59
2.09
1.1
1.2
—
—
—
0
0
133
1627
0.76
2.06
3.7
4.3
20.12
21.45
%
0.50
50
749
9
32
2.84
2.01
1.2
1.5
—
—
—
0
0
235
2045
1.27
1.94
3.4
2.9
144.04
142.42
ug/l
0.04
211
1920
85
643
1.38
1.93
2.0
1.9
1.91
1.52
%
2.40
74
573
17
85
2.03
1.92
4.2
3.9
16.29
10.43
pmol/l
0.53
17
85
452
4277
1.36
1.84
27.7
15.7
83.03
81.95
ml/min/173m2
0.45
436
3961
58
417
1.44
1.77
3.4
2.9
4.45
4.42
kpa
0.05
58
406
128
1050
1.29
1.68
1.7
1.7
1.31
1.20
mg/l
0.16
101
819
35
518
0.65
1.66
2.0
2.0
3.59
3.61
ratio
0.02
28
418
6
19
3.18
1.66
1.3
1.0
—
—
—
0
0
16
83
1.96
1.66
1.2
1.6
—
—
—
0
0
53
380
1.44
1.65
2.6
2.6
7.73
8.36
ug/l
0.09
42
342
72
933
0.74
1.64
3.4
4.0
944.74
451.12
ng/l
0.50
54
736
22
128
1.75
1.63
1.3
1.3
—
2.20
—
0
7
21
121
1.77
1.60
1.3
1.3
—
2.89
—
0
19
357
3300
1.24
1.60
5.1
3.9
14.73
14.82
pmol/l
0.26
320
3024
48
342
1.44
1.55
1.8
1.5
—
—
—
0
0
7
27
2.61
1.52
2.3
3.7
0.43
0.78
%
—
7
27
7
27
2.61
1.52
2.1
1.5
—
—
—
0
0
21
125
1.71
1.45
3.0
2.3
7670.26
5060.21
u/l
—
10
50
40
558
0.69
1.43
5.3
4.7
27.24
31.06
%
1.97
29
378
9
41
2.22
1.37
1.3
1.2
—
—
—
0
0
6
23
2.63
1.37
1.0
1.1
189.33
230.58
iu/ml
—
6
23
21
129
1.65
1.32
1.4
1.5
257.67
279.43
ug/g
0.18
12
80
22
137
1.63
1.31
2.5
2.5
237.50
122.02
ug/min
0.36
12
79
94
766
1.28
1.31
1.6
1.5
—
—
—
0
0
9
43
2.11
1.31
1.0
1.1
—
79.00
—
0
6
5
18
2.79
1.28
2.0
3.7
9.60
10.61
kpa
—
5
18
5
18
2.79
1.28
2.0
3.7
5.91
4.65
kpa
—
5
18
26
383
0.66
1.25
1.5
1.8
3.32
3.47
mmol/l
0.29
19
285
61
774
0.76
1.21
3.5
3.0
1.99
1.74
e6/l
0.13
36
392
0
34
0.00
1.16
0.0
1.1
—
—
—
0
0
33
233
1.44
1.16
1.7
1.7
0.50
0.34
mg/l
0.58
20
113
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
21
134
1.59
1.16
2.9
2.3
0.39
0.34
iu/ml
0.21
12
71
8
40
2.01
1.12
1.0
1.5
—
—
—
0
0
17
104
1.66
1.10
1.7
1.5
—
—
—
0
0
5
21
2.39
1.09
1.8
1.5
395.40
968.00
e6/l
—
5
16
308
2870
1.17
1.04
6.5
4.4
1286.07
1418.47
e6/l
0.03
15
43
9
46
1.97
1.04
3.6
2.2
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
5
22
2.28
1.03
1.4
1.2
—
—
—
0
0
24
163
1.49
1.03
1.3
2.4
11.42
10.83
g/l
0.10
17
148
16
249
0.63
1.01
2.6
2.0
—
—
—
0
0
36
479
0.73
1.01
1.7
1.5
—
—
—
0
0
96
810
1.23
1.00
1.4
1.3
24.64
31.44
iu/ml
0.48
28
246
95
802
1.22
0.99
2.0
2.0
—
—
—
0
0
5
23
2.18
0.98
2.6
2.7
900.40
790.78
u/ml
—
5
23
13
209
0.61
0.95
1.2
1.3
—
—
—
0
0
7
37
1.90
0.94
1.3
1.3
112.57
96.81
pmol/l
—
7
37
144
1272
1.18
0.93
2.1
1.7
20.22
19.85
nmol/l
0.08
118
1079
436
4198
1.21
0.93
6.4
4.3
1.45
1.32
mmol/l
2.35
412
3895
9
52
1.74
0.92
1.2
1.5
50.14
59.51
ug/l
—
9
52
25
176
1.44
0.92
2.5
2.0
—
—
—
0
0
334
3151
1.16
0.90
5.0
3.4
75.78
52.59
u/l
2.67
315
2983
222
2035
1.15
0.89
8.1
6.7
1.20
1.21
mmol/l
1.12
203
1890
13
205
0.63
0.89
2.8
1.9
—
—
—
0
0
466
4521
1.23
0.89
25.2
19.2
4.00
3.99
mmol/l
0.34
454
4438
17
111
1.55
0.88
1.2
1.2
—
—
—
0
0
16
103
1.57
0.88
1.2
1.6
—
—
—
0
0
23
161
1.45
0.88
2.1
1.8
—
—
—
0
0
26
189
1.39
0.82
1.4
2.4
7.24
7.34
g/l
0.10
20
175
26
189
1.39
0.82
1.4
2.4
4.42
4.21
g/l
0.70
20
175
26
189
1.39
0.82
1.4
2.4
3.67
3.68
g/l
0.03
20
175
21
147
1.45
0.81
1.2
1.3
98.67
246.91
miu/ml
—
6
67
17
114
1.51
0.80
1.5
1.4
—
—
—
0
0
10
58
1.74
0.80
1.6
1.2
—
—
—
0
0
464
4511
1.21
0.79
25.2
19.0
139.24
139.66
mmol/l
3.22
451
4435
7
122
0.57
0.79
1.1
1.3
—
—
—
0
0
0
26
0.00
0.78
0.0
1.5
—
—
—
0
0
0
27
0.00
0.77
0.0
1.1
—
—
—
0
0
6
34
1.77
0.76
4.7
3.6
29.83
61.67
u/ml
—
6
34
217
2007
1.14
0.74
2.3
2.1
93.31
95.73
pmol/l
0.33
135
1096
9
55
1.65
0.74
1.3
2.2
—
—
—
0
0
20
143
1.41
0.71
1.5
1.6
—
—
—
0
0
5
26
1.93
0.71
1.0
3.3
—
491.80
—
0
5
10
62
1.62
0.65
1.4
2.1
—
—
—
0
0
7
44
1.60
0.65
1.4
1.9
—
—
—
0
0
7
44
1.60
0.65
1.4
1.9
—
—
—
0
0
7
44
1.60
0.65
1.4
1.9
—
—
—
0
0
476
4660
1.19
0.60
25.7
12.2
29.10
28.03
u/l
0.67
471
4545
36
438
0.81
0.57
3.5
2.5
61.00
153.96
u/l
0.39
31
369
33
266
1.26
0.57
1.7
1.5
—
—
—
0
0
227
2134
1.11
0.56
3.4
2.9
—
—
estimate
—
0
0
163
1507
1.12
0.55
2.9
3.3
2.33
2.35
mmol/l
1.08
150
1374
192
2051
0.90
0.54
4.2
5.1
1.67
2.33
ug/l
1.97
172
1861
117
1062
1.13
0.54
5.9
3.8
1.02
1.02
kg/l
0.70
94
715
430
4190
1.13
0.53
8.4
6.4
40.94
39.50
mmol/mol
2.37
398
3952
16
117
1.38
0.53
1.3
1.5
—
—
—
0
0
58
501
1.18
0.52
12.3
7.1
—
—
—
0
0
450
4400
1.14
0.51
7.2
5.1
4.41
4.57
mmol/l
2.95
427
4130
11
75
1.48
0.51
1.0
1.1
1.64
1.51
g/l
0.89
11
67
63
551
1.16
0.49
4.3
3.2
7.72
8.54
umol/l
0.24
51
501
21
163
1.30
0.49
1.5
2.6
1.32
1.27
g/l
0.02
16
146
74
829
0.88
0.47
3.1
2.9
0.98
1.11
e6/l
0.15
50
447
44
377
1.18
0.45
1.3
1.4
—
—
—
0
0
12
86
1.40
0.45
1.5
1.4
—
—
—
0
0
0
15
0.00
0.41
0.0
1.2
—
0.63
—
0
9
0
17
0.00
0.40
0.0
1.8
—
57.57
—
0
17
13
97
1.35
0.40
1.4
1.2
—
44.17
—
0
15
8
61
1.32
0.39
1.4
1.7
—
—
—
0
0
22
179
1.24
0.38
1.5
2.4
2.72
3.07
g/l
1.51
16
165
31
264
1.18
0.35
1.1
1.2
38.60
155.51
u/ml
—
10
107
22
181
1.22
0.35
3.1
2.9
—
—
—
0
0
13
101
1.29
0.32
1.2
1.5
—
—
—
0
0
7
55
1.28
0.30
1.4
1.2
1.46
1.52
nmol/l
—
7
50
13
103
1.27
0.28
1.2
1.5
—
—
—
0
0
35
309
1.14
0.27
4.3
4.0
83.43
87.16
ng/l
0.11
25
272
9
75
1.20
0.25
1.2
1.7
—
—
—
0
0
63
581
1.10
0.25
10.0
8.0
1.32
0.77
mmol/l
0.40
48
490
6
82
0.73
0.24
1.2
1.3
—
—
—
0
0
6
82
0.73
0.24
1.2
1.3
—
—
—
0
0
43
473
0.90
0.23
4.0
4.9
7.84
36.40
ug/l
0.95
34
396
11
88
1.26
0.22
2.3
1.3
—
159.97
—
0
23
7
91
0.77
0.22
1.3
1.7
—
—
—
0
0
15
125
1.21
0.22
3.6
3.2
2.00
2.09
index
—
6
80
5
40
1.25
0.22
1.0
1.2
—
—
—
0
0
5
40
1.25
0.22
1.0
1.2
—
—
—
0
0
62
575
1.09
0.22
1.5
2.0
—
—
—
0
0
5
41
1.22
0.22
1.0
1.0
242.80
279.08
mg/l
—
5
36
5
42
1.19
0.21
1.0
1.1
—
68.00
—
0
5
0
11
0.00
0.21
0.0
1.5
—
—
—
0
0
8
105
0.76
0.21
1.3
1.3
—
—
—
0
0
5
43
1.16
0.21
1.0
1.3
288.20
173.58
pmol/l
—
5
43
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
6
49
1.23
0.20
1.0
1.7
—
—
—
0
0
21
237
0.88
0.18
2.1
4.1
3.84
4.59
pmol/l
2.85
14
214
7
61
1.15
0.17
1.3
1.4
—
—
—
0
0
432
4273
1.06
0.17
5.8
5.0
6.20
6.01
mmol/l
2.12
393
3948
10
120
0.83
0.16
1.1
1.1
—
—
—
0
0
14
162
0.86
0.16
1.1
1.2
—
—
—
0
0
408
4034
1.05
0.16
5.9
4.9
2.05
1.91
mu/l
1.33
372
3728
10
119
0.84
0.15
1.1
1.1
—
—
—
0
0
281
2760
1.04
0.15
2.8
3.0
—
—
—
0
0
442
4381
1.05
0.14
6.2
5.0
1.34
1.40
mmol/l
2.89
410
4089
18
199
0.90
0.11
1.1
1.0
—
—
—
0
0
11
95
1.16
0.11
1.2
1.2
226.33
259.56
u/ml
—
6
48
16
144
1.11
0.10
1.4
1.8
85.87
90.83
%
0.32
16
139
14
156
0.89
0.10
1.3
1.6
—
—
—
0
0
5
47
1.06
0.09
1.0
1.1
—
—
—
0
0
5
47
1.06
0.09
4.2
3.3
3.88
3.29
nmol/l
—
5
47
6
54
1.11
0.09
1.0
1.1
—
—
—
0
0
6
56
1.07
0.08
1.0
1.1
—
—
—
0
0
5
61
0.82
0.08
1.4
1.4
—
—
—
0
0
6
71
0.84
0.07
1.2
1.1
—
—
—
0
0
448
4458
1.03
0.07
6.8
5.7
2.60
2.70
mmol/l
1.68
417
4164
15
138
1.09
0.06
1.1
1.4
—
—
—
0
0
28
292
0.96
0.04
1.5
1.7
—
—
—
0
0
13
140
0.93
0.04
1.2
2.4
11.63
12.46
mg/l
0.12
13
130
47
457
1.03
0.04
2.3
2.0
—
—
—
0
0
37
358
1.04
0.04
3.1
2.8
55.24
66.46
ml/min/173m2
1.18
17
154
110
1115
0.98
0.03
3.6
2.5
—
—
—
0
0
62
609
1.02
0.03
1.6
1.9
—
—
—
0
0
17
163
1.04
0.01
1.1
1.1
1.44
1.48
g/l
0.21
17
163
51
502
1.02
0.01
2.2
2.1
—
—
—
0
0
17
171
0.99
0.00
1.1
1.2
0.83
0.90
g/l
0.33
17
171
189
1885
1.00
0.00
2.6
2.0
1.48
1.43
mmol/l
0.40
145
1611
6
60
1.00
-0.00
1.3
1.5
—
—
—
0
0
7
73
0.96
-0.00
1.3
1.5
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
8
0.00
-0.00
0.0
2.9
—
43.88
—
0
8
6
59
1.02
-0.00
1.3
1.5
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.3
—
—
—
0
0
15
150
1.00
-0.00
1.1
1.2
—
—
—
0
0
7
71
0.99
-0.00
1.1
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.9
—
1.24
—
0
9
5
49
1.02
-0.00
1.0
1.2
—
—
—
0
0
6
60
1.00
-0.00
1.3
1.5
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
6
59
1.02
-0.00
1.3
1.5
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint L12_ERYTHRO_KELA and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| L12_ERYTHRO_KELA | 1.756 [1.38, 2.24] | < 0.001 |
| Birth year | 0.994 [0.99, 1.0] | 0.201 |
During the follow-up period (1.1.1998 — 31.12.2019), 107 out of 680 females with L12_ERYTHRO_KELA died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| L12_ERYTHRO_KELA | 1.919 [1.61, 2.28] | < 0.001 |
| Birth year | 0.991 [0.98, 1.0] | 0.062 |
During the follow-up period (1.1.1998 — 31.12.2019), 254 out of 1333 males with L12_ERYTHRO_KELA died.
Mortality risk
Mortality risk for people of age
years, who have L12_ERYTHRO_KELA.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.161% | 0.426% |
| 5 | 0.981% | 2.332% |
| 10 | 2.483% | 6.368% |
| 15 | 4.943% | 11.795% |
| 20 | 8.337% | 19.381% |
Relationships between endpoints
↥Index endpoint: L12_ERYTHRO_KELA – Universal erythroderma, KELA reimbursement
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data